Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Unknown 4Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Advanced Solid Cancer 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × SH-1028 × Clear all
NCT04239833 2020-01-27

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 3 Unknown
240 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03823807 2019-02-01

A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2 Unknown
300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03618043 2019-01-29

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 1 Unknown
14 enrolled

Advanced Solid Cancer

NCT03603262 2019-01-28

Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 1 Unknown
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡